News &amp; Updates

Patients with inflammatory bowel disease (IBD) who achieve a normal C-reactive protein (CRP) and endoscopic healing exhibit significantly higher ustekinumab trough levels, reveals a study. A cutoff level of 4.8 µg/mL predicts CRP normalization.

Ustekinumab levels higher in IBD patients with normal CRP, endoscopic healing

Anti-CGRP monoclonal antibodies pose no increased CVD risk

Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor do not appear to contribute to heightened risk of cardiovascular disease (CVD) relative to onabotulinumtoxinA in adults with migraine at high CVD risk, according to a study.

Anti-CGRP monoclonal antibodies pose no increased CVD risk

Blinatumomab plus chemo improves survival in paediatric B-ALL

Chemotherapy combined with blinatumomab (blin) delivers significant improvements in disease-free survival (DFS) in children with newly diagnosed National Cancer Institute standard risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL), according to the results of the AALL1731 study presented at ASH 2024.

Blinatumomab plus chemo improves survival in paediatric B-ALL

10 Jan 2025

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

The addition of tafasitamab (tafa) to lenalidomide and rituximab (len+R) significantly improves progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL), as shown in a phase III study presented at ASH 2024. The safety profile of this combination is manageable and consistent with expected toxicities.

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

10 Jan 2025

Survival benefit with STRIDE for HCC sustained at 5 years

The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).

Survival benefit with STRIDE for HCC sustained at 5 years

10 Jan 2025

LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

Treatment with belzutifan improves progression-free survival (PFS) and objective response rate (ORR) in East Asian patients with advanced clear-cell renal cell carcinoma (RCC) compared with everolimus, according to the updated subgroup data of the phase III LITESPARK-005 trial presented at ESMO Asia 2024.

LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

10 Jan 2025

Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen

09 Jan 2025 by

Adjuvant use of tamoxifen is associated with a big drop in the risk of recurrence in the same breast among patients with “good-risk” ductal carcinoma in situ (DCIS) after breast-conserving surgery without radiotherapy.

Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen

Rilzabrutinib delivers beneficial effects in immune thrombocytopenia

09 Jan 2025 by

A phase III trial (LUNA 3) has demonstrated robust therapeutic effects for rilzabrutinib in patients with previously untreated immune thrombocytopenia (ITP). Use of this BTK inhibitor results in rapid and durable platelet response, reduced bleeding and need for rescue therapy, improved physical fatigue and quality of life (QoL), and favourable safety and tolerability.

Rilzabrutinib delivers beneficial effects in immune thrombocytopenia

Ceftolozane–tazobactam for resistant P. aeruginosa infections linked to high clinical success

In the treatment of invasive infections due to multidrug-resistant P. aeruginosa, the use of ceftolozane–tazobactam combination appears to yield higher rates of clinical success than the ceftazidime–avibactam combination, according to an observational study.

Ceftolozane–tazobactam for resistant P. aeruginosa infections linked to high clinical success